AbbVie Inc.: výsledky za 3. štvrťrok 2026
Zverejnené 29. 10. 2026, pred otvorením burzy. Zisk na akciu – oproti odhadu 3,84.
AI zhrnutie
AIZhrnutie ukáže, ako výsledky dopadli, čo firma splnila, výhody a nevýhody a prečo akcia zareagovala tak, ako zareagovala.
Tlačová správa firmy
Otvoriť na SECPrepis telefonického hovoru s analytikmi je chránený autorským právom, preto tu ukazujeme verejnú tlačovú správu.
Zobraziť celý text (anglicky)
2
abbv-20260930nonxgaapxex991.htm
EX-99.1
AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
|
| (in millions, except per share data) | Quarter Ended September 30, 2026 | Full-Year Ended December 31, 2026
| Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range
| Low | High | Low | High
|
Previously announced guidance excluding Q3 2026 acquired IPR&D and milestones expense
| $ | — | $ | 3.84 | $ | 3.88 | $ | 1,035 | $ | 13.87 | $ | 14.07 |
| Q3 2026 acquired IPR&D and milestones expense | 216 | (0.11) | (0.11) | 216 | (0.11) | (0.11) |
|
Guidance including Q3 2026 acquired IPR&D and milestones expensea
| $ | 216 | $ | 3.73 | $ | 3.77 | $ | 1,251 | $ | 13.76 | $ | 13.96 |
a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted.
1